Although Cinar R et al. found that the overactivity of CB1 contributed to the pathogenesis of IPF (Cinar et al., 2017), the CB1R inhibitor rimonabant had no significant efficacy in stopping progression of fibrosis or reversing established fibrosis (Cinar et al., 2016), the pathology of liver fibrosis was still evident in CB1R knockout mice as well (Teixeira-Clerc et al., 2006; Cinar et al., 2016). This evidence concerns the gene CNR1 and Hepatic fibrosis.